Intervention

Dalteparin

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions21

Lead sponsors shown8

Clinical trials

8 shown

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTENCT05171075 · 2022-09-27

WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous ThromboembolismNCT03297359 · 2018-03-21

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerNCT02744092 · 2016-12-13

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous ThromboembolismNCT02585713 · 2015-11-20

Cancer Venous Thromboembolism (VTE)NCT02073682 · 2015-07-16

Venous Thromboprophylaxis in Bariatric SurgeryNCT03218514 · 2014-07-01

Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer PatientsNCT00966277 · 2010-04-01

LMWH to Prevent Preeclampsia and Fetal Growth RestrictionNCT00260520 · 2002-01-01

Common conditions

Leading sponsors

Academic and Community Cancer Research United1 Alliance Foundation Trials, LLC.1 Anthos Therapeutics, Inc.1 Daiichi Sankyo1 Groupe Hospitalier Pitie-Salpetriere1 M.D. Anderson Cancer Center1 Ottawa Hospital Research Institute1 University of Florence1

Trial status mix

COMPLETED5

TERMINATED3

Phase mix

PHASE33

NA1

PHASE21

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.